Maintenance immunosuppressive therapy in adult renal transplantation: A single center analysis

Sayegh, 2004, Transplantation 50 years later-progress, challenges, and promises, N Engl J Med, 351, 2761, 10.1056/NEJMon043418 Meier-Kriesche, 2004, Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era, Am J Transplant, 4, 378, 10.1111/j.1600-6143.2004.00332.x Meier-Kriesche, 2004, Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies?, Am J Transplant, 4, 1289, 10.1111/j.1600-6143.2004.00515.x Womer, 2000, Chronic allograft dysfunction: mechanisms and new approaches to therapy, Semin Nephrol, 20, 126 Najafian, 2008, Chronic allograft nephropathy, Curr Opin Nephrol Hypertens, 17, 149, 10.1097/MNH.0b013e3282f4e514 Davidson, 2003, New-onset diabetes after transplantation: 2003 international consensus guidelines, vol. 75 (10 Suppl), SS3 Andany, 2001, Dyslipidemia and its management after renal transplantation, J Nephrol, 14, S81 Hirsch, 2006, The natural history, risk factors and outcomes of polyomavirus BK-associated nephropathy after renal transplantation, Nat Clin Pract Nephrol, 2, 240, 10.1038/ncpneph0179 Kasiske, 2000, Cardiovascular disease after renal transplantation, Semin Nephrol, 20, 176 Meyers, 2005, Workshop on late renal allograft dysfunction, Am J Transplant, 5, 1600, 10.1111/j.1600-6143.2005.00926.x Kingston, 2006, Chronic renal allograft dysfunction: the evidence for a change in immunosuppression, Minerva Urol Nefrol, 58, 23 Danovitch, 2001, Immunosuppressive medications for renal transplantation: a multiple choice question, Kidney Int, 59, 388, 10.1046/j.1523-1755.2001.00501.x Shapiro, 2005, Immunosuppression: evolution in practice and trends, 1993–2003, Am J Transplant, 5, 874, 10.1111/j.1600-6135.2005.00833.x Samaniego, 2006, Drug insight: maintenance immunosuppression in kidney transplant recipients, Nat Clin Pract Nephrol, 2, 688, 10.1038/ncpneph0343 Kirk, 2006, Meteorology and tolerance, Am J Transplant, 6, 645, 10.1111/j.1600-6143.2006.01244.x Nankivell, 2003, The natural history of chronic allograft nephropathy, N Engl J Med, 349, 2326, 10.1056/NEJMoa020009 Kasiske, 2000, Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation, J Am Soc Nephrol, 11, S1, 10.1681/ASN.V11suppl_1s1 Hardinger, 2004, Current and future immunosuppressive strategies in renal transplantation, Pharmacotherapy, 24, 1159, 10.1592/phco.24.13.1159.38094 Ekberg, 2007, No robust conclusions to be drawn from clinical trials in the absence of an adequate control group, Transpl Int, 20, 25, 10.1111/j.1432-2277.2006.00428.x Meier-Kriesche, 2006, Immunosuppression: evolution in practice and trends, 1994–2004, Am J Transplant, 6, 1111, 10.1111/j.1600-6143.2006.01270.x Meier-Kriesche, 2006, Are we ready to give up on calcineurin inhibitors?, Am J Transplant, 6, 445, 10.1111/j.1600-6143.2006.01233.x Hojo, 1999, Cyclosporine induces cancer progression by a cell-autonomous mechanism, Nature, 397, 530, 10.1038/17401 Dantal, 1998, Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens, Lancet, 351, 623, 10.1016/S0140-6736(97)08496-1 Cantarovich, 2008, Immunosuppression minimization in kidney transplantation, Front Biosci, 13, 1413, 10.2741/2771 Kaplan, 2003, Long-term graft survival with neoral and tacrolimus: a paired kidney analysis, J Am Soc Nephrol, 14, 2980, 10.1097/01.ASN.0000095250.92361.D5 Webster, 2005, Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data, BMJ, 331, 810, 10.1136/bmj.38569.471007.AE Bowman, 2008, The role of tacrolimus in renal transplantation, Expert Opin Pharmacother, 9, 635, 10.1517/14656566.9.4.635 Joss, 2007, Predictors of new onset diabetes after renal transplantation, Clin Transplant, 21, 136, 10.1111/j.1399-0012.2006.00580.x Maes, 2001, Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors, Transplantation, 72, 1655, 10.1097/00007890-200111270-00014 van Hooff, 2004, Evaluating mechanisms of post-transplant diabetes mellitus, Nephrol Dial Transplant, 19, vi8, 10.1093/ndt/gfh1063 Kasiske, 2003, Diabetes mellitus after kidney transplantation in the United States, Am J Transplant, 3, 178, 10.1034/j.1600-6143.2003.00010.x Kuypers, 2008, Early clinical assessment of glucose metabolism in renal allograft recipients: diagnosis and prediction of post-transplant diabetes mellitus (PTDM), Nephrol Dial Transplant, 23, 2033, 10.1093/ndt/gfm875 Weng, 2008, Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial, Lancet, 371, 1753, 10.1016/S0140-6736(08)60762-X Vincenti, 2007, Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus, Am J Transplant, 7, 1506, 10.1111/j.1600-6143.2007.01749.x Smak Gregoor, 2002, Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study, J Am Soc Nephrol, 13, 1365, 10.1097/01.ASN.0000013298.11876.BF Gelens, 2006, High rejection rate during calcineurin inhibitor-free and early steroid withdrawal immunosuppression in renal transplantation, Transplantation, 82, 1221, 10.1097/01.tp.0000232688.76018.19 Ekberg, 2007, Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study, Am J Transplant, 7, 560, 10.1111/j.1600-6143.2006.01645.x Ekberg, 2007, Reduced exposure to calcineurin inhibitors in renal transplantation, N Engl J Med, 357, 2562, 10.1056/NEJMoa067411 Pascual, 2003, A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation, Transplantation, 75, 1501, 10.1097/01.TP.0000061606.64917.BE Batiuk, 1995, Cyclosporine inhibition of calcineurin activity in human leukocytes in vivo is rapidly reversible, J Clin Invest, 96, 1254, 10.1172/JCI118159 Batiuk, 1995, Calcineurin activity is only partially inhibited in leukocytes of cyclosporine-treated patients, Transplantation, 59, 1400, 10.1097/00007890-199505270-00007 Birsan, 2004, Comparison between C0 and C2 monitoring in de novo renal transplant recipients: retrospective analysis of a single-center experience, Transplantation, 78, 1787, 10.1097/01.TP.0000146255.30770.76 Hecking, 2008, Analysis of liver function in renal transplant recipients undergoing C2-monitoring for cyclosporine, Transpl Int, 21, 223, 10.1111/j.1432-2277.2007.00563.x Mulay, 2005, Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials, Am J Transplant, 5, 1748, 10.1111/j.1600-6143.2005.00931.x Thaunat, 2005, Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state, Transplantation, 80, 1212, 10.1097/01.tp.0000179106.07382.6a Vogelbacher, 2007, The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat, Transplantation, 84, 1492, 10.1097/01.tp.0000282866.92367.99 Letavernier, 2007, High sirolimus levels may induce focal segmental glomerulosclerosis de novo, Clin J Am Soc Nephrol, 2, 326, 10.2215/CJN.03751106 Weiner, 2007, Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome-a single-centre experience and review of the literature, Nephrol Dial Transplant, 22, 3631, 10.1093/ndt/gfm420 Witzig, 2005, Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma, J Clin Oncol, 23, 5347, 10.1200/JCO.2005.13.466 Hutson, 2007, Evolving role of novel targeted agents in renal cell carcinoma, Oncology (Williston Park), 21, 1175 Stallone, 2005, Sirolimus for Kaposi's sarcoma in renal-transplant recipients, N Engl J Med, 352, 1317, 10.1056/NEJMoa042831 Descoeudres, 2006, No effect of sirolimus for kaposi sarcoma in a renal transplant recipient, Transplantation, 81, 1472, 10.1097/01.tp.0000203322.99037.d2 Lebbe, 2006, Sirolimus conversion for patients with posttransplant Kaposi's sarcoma, Am J Transplant, 6, 2164, 10.1111/j.1600-6143.2006.01412.x Boratynska, 2006, Reccurence of Kaposi's sarcoma after increased exposure to sirolimus, Int Immunopharmacol, 6, 2018, 10.1016/j.intimp.2006.09.018 Babel, 2008, Development of Kaposi's sarcoma under sirolimus-based immunosuppression and successful treatment with imiquimod, Transpl Infect Dis, 10, 59, 10.1111/j.1399-3062.2007.00239.x Prestwich, 2008, The immune system-is it relevant to cancer development, progression and treatment?, Clin Oncol (R Coll Radiol), 20, 101, 10.1016/j.clon.2007.10.011 Dittrich, 2004, Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy, Transpl Int, 17, 215, 10.1111/j.1432-2277.2004.tb00431.x Säemann, 2000, Suppression of primary T-cell responses and induction of alloantigen-specific hyporesponsiveness in vitro by the Janus kinase inhibitor tyrphostin AG490, Transplantation, 70, 1215, 10.1097/00007890-200010270-00016 Weichhart, 2008, Biological action of rapamycin in renal transplantation, Am J Kidney Dis, 51, 531, 10.1053/j.ajkd.2007.09.027 Augustine, 2006, Steroid sparing in kidney transplantation: changing paradigms, improving outcomes, and remaining questions, Clin J Am Soc Nephrol, 1, 1080, 10.2215/CJN.01800506 Matas, 2005, Prednisone-free maintenance immunosuppression-a 5-year experience, Am J Transplant, 5, 2473, 10.1111/j.1600-6143.2005.01051.x Ahsan, 1999, Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil — a prospective randomized study. Steroid Withdrawal Study Group, Transplantation, 68, 1865, 10.1097/00007890-199912270-00009 Vanrenterghem, 2000, Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection, Transplantation, 70, 1352, 10.1097/00007890-200011150-00015 Pascual, 2006, Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant, Transplantation, 82, 55, 10.1097/01.tp.0000225806.80890.5e Augustine, 2007, Minimization of immunosuppression in kidney transplantation, Curr Opin Nephrol Hypertens, 16, 535, 10.1097/MNH.0b013e3282f0b319 Laftavi, 2005, Randomized prospective trial of early steroid withdrawal compared with low-dose steroids in renal transplant recipients using serial protocol biopsies to assess efficacy and safety, Surgery, 137, 364, 10.1016/j.surg.2004.10.013 van den Ham, 2003, Weight changes after renal transplantation: a comparison between patients on 5-mg maintenance steroid therapy and those on steroid-free immunosuppressive therapy, Transpl Int, 16, 300, 10.1111/j.1432-2277.2003.tb00304.x Opelz, 2005, Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients, Am J Transplant, 5, 720, 10.1111/j.1600-6143.2004.00765.x Calne, 2005, “Prope” tolerance: induction, lymphocyte depletion with minimal maintenance, Transplantation, 80, 6, 10.1097/01.TP.0000164351.72220.1A Roussey-Kesler, 2006, Clinical operational tolerance after kidney transplantation, Am J Transplant, 6, 736, 10.1111/j.1600-6143.2006.01280.x Colvin, 2007, Antibody-mediated renal allograft rejection: diagnosis and pathogenesis, J Am Soc Nephrol, 18, 1046, 10.1681/ASN.2007010073 Tinckam, 2006, Mechanisms and role of HLA and non-HLA alloantibodies, Clin J Am Soc Nephrol, 1, 404, 10.2215/CJN.00270106